Treatment of acute myelogenous leukemia in the elderly

R. E. Champlin, J. L. Gajewski, D. W. Golde

    Research output: Contribution to journalReview article

    40 Scopus citations

    Abstract

    Current data indicate that most elderly patients with acute myelogenous leukemia should be treated with intensive chemotherapy. Most should receive remission induction chemotherapy using cytarabine 100 to 200 mg/m2/d by constant intravenous infusion for five to seven days plus daunorubicin ≥ 30 mg/m2/d for three days. Patients in good overall condition with a near-normal performance status may benefit from a more intensive regimen. Patients achieving remission should receive one to three courses of consolidation chemotherapy. Highly debilitated patients have poor results with any form of therapy, and there has been no apparent advantage for low-dose chemotherapy compared to standard treatment regimens. The intensity of chemotherapy must be individualized to the requirements of the patients.

    Original languageEnglish (US)
    Pages (from-to)51-56
    Number of pages6
    JournalSeminars in Oncology
    Volume16
    Issue number1
    StatePublished - Jan 1 1989

    ASJC Scopus subject areas

    • Hematology
    • Oncology

    Fingerprint Dive into the research topics of 'Treatment of acute myelogenous leukemia in the elderly'. Together they form a unique fingerprint.

  • Cite this

    Champlin, R. E., Gajewski, J. L., & Golde, D. W. (1989). Treatment of acute myelogenous leukemia in the elderly. Seminars in Oncology, 16(1), 51-56.